US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Research & Development Market Research Reports & Industry Analysis

The term research and development (R&D) refers to work that is done in order to better understand the nature, function or understanding of a topic or product in order to gain knowledge and find new applications for existing products or to develop new and innovative products. This is usually performed by corporations, government agencies, and research or academic institutions.

New product design and development is essential for the survival and growth of many companies, as markets and consumers’ tastes are fickle and the competition can be fierce. In order to stay relevant in a fast changing marketplace, firms have to constantly revise and expand their range of product offerings. Therefore, research and development is of great economic importance as companies fight to maintain their market share, though it may mean forgoing current profits in favor of potential future performance and returns.

Research and development is most often associated with the technology industry, as well as with science and in particular with healthcare and the development of new pharmaceuticals, diagnostics or medical devices that are safe and effective. For instance, drug makers must constantly search for the next big blockbuster drug, since the products they currently have on the market will eventually lose their patent protection and be vulnerable to generic competition. So they spend huge amounts of money on R&D because without a promising drug pipeline their revenue stream will ultimately dry up.

RSS Feeds

Research & Development Industry Research & Market Reports

< prev 1    3  4  5  6  7  8  9  10  
Global Colorectal Cancer Drugs Market 2015-2019
6/17/2015 | published by: TechNavio - Infiniti Research Ltd.
... most common feature of colorectal cancer. The cancer starts as a polyp in the inner wall of the colon or rectum. These polyps can be benign or malignant. Colorectal cancer is the third most common ...  |  read more...
USD 3,000
Scientific Research and Development (R&D) Industry, in Physics, Engineering, Life Sciences, Drugs, Telecommunications and Electronics Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2022, NAIC 541710
6/29/2015 | published by: Plunkett Research, Ltd.
... benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Key Findings: Scientific Research and Development (R&D) Industry, in Physics, Engineering, Life Sciences, Drugs, Telecommunications and Electronics Industry (U.S.) to reach ...  |  read more...
USD 1,995
T Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2015
6/17/2015 | published by: BioSeeker Group AB
... cell receptor signaling. There are today 319 companies plus partners developing 404 T cell receptor pathway targeting drugs in 1601 developmental projects in cancer. In addition, there are 6 suspended drugs and the accumulated number ...  |  read more...
USD 6,750
TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update 2015
6/17/2015 | published by: BioSeeker Group AB
... in 1794 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 261 drugs. Tgf-Beta Receptor Signaling Pathway In Oncology ...  |  read more...
USD 6,750
Expression Vectors Market by Host Type (Bacterial/E.Coli, Mammalian/CHO, Insect/Baculovirus, and Yeast), Application (Therapeutic, Research, and Industrial), End User (Pharmaceutical, Biotechnology, CROs & CMOs, and Academic Research) - Forecast to 2020
6/16/2015 | published by: MarketsandMarkets
... is expected to reach $317.1 million by 2020 from $242.7 million in 2015, growing at a CAGR of 5.5% from 2015 to 2020. The market is categorized on the basis of host type, application, end ...  |  read more...
USD 4,650
TSH Signaling Pathway in Oncology Drug Pipeline Update 2015
6/17/2015 | published by: BioSeeker Group AB
... it will give signaling to NF-kappa B, mitogen activated protein kinases, protein kinase C modules. There are today 215 companies plus partners developing 294 TSH pathway targeting drugs in 1291 developmental projects in cancer. In ...  |  read more...
USD 6,750
Alpha6 Beta4 Integrin Signaling Pathway in Oncology Drug Pipeline Update 2015
6/17/2015 | published by: BioSeeker Group AB
... 464 Alpha6Beta4 integrin pathway targeting drugs in 1712 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 201 drugs. ...  |  read more...
USD 6,750
Angiogenesis in Oncology Drug Pipeline Update 2015
6/17/2015 | published by: BioSeeker Group AB
... number of ceased drugs over the last years amount to another 215 drugs. Angiogenesis In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs ...  |  read more...
USD 6,750
Apoptosis in Oncology Drug Pipeline Update 2015
6/17/2015 | published by: BioSeeker Group AB
... cancer cells. There are today 426 companies plus partners developing 550 apoptotic drugs in 2563 developmental projects in cancer. In addition, there are 11 suspended drugs and the accumulated number of ceased drugs over the ...  |  read more...
USD 6,750
B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2015
6/17/2015 | published by: BioSeeker Group AB
... leads to activation of several non-receptor tyrosine kinases including those of the Src, Tec and Syk family of kinases. Downstream messengers include DAG, IP3, MAPK/ERK and JNK signaling modules. There are today 278 companies plus ...  |  read more...
USD 6,750
Biologicals in Oncology Drug Pipeline Update 2015
6/17/2015 | published by: BioSeeker Group AB
... developing 2333 biological drugs in 5702 developmental projects in cancer. In addition, there are 27 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 1017 drugs. Biologicals In ...  |  read more...
USD 11,025
Bladder Cancer Drug Pipeline Update 2015
6/17/2015 | published by: BioSeeker Group AB
... treated early, the 5 year survival rate is 94%. There are today 122 companies plus partners developing 149 drugs targeting bladder cancer in development. In addition, there are 3 suspended drugs and the accumulated number ...  |  read more...
USD 4,485
Brain Cancer Drug Pipeline Update 2015
6/17/2015 | published by: BioSeeker Group AB
... deadly diseases in the developed world. While primary brain tumors are relatively rare, the chances of survival for patients with the disease are very low, even with the best treatment options currently available. There are ...  |  read more...
USD 6,750
Breast Cancer Drug Pipeline Update 2015
6/17/2015 | published by: BioSeeker Group AB
... and metastatic setting, the overall survival remains below five years. There are today 573 companies plus partners developing 699 drugs targeting breast cancer in development. In addition, there are 8 suspended drugs and the accumulated ...  |  read more...
USD 6,750
EGFR1 Signaling Pathway in Oncology Drug Pipeline Update 2015
6/17/2015 | published by: BioSeeker Group AB
... projects in cancer. In addition, there are 5 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 365 drugs. Egfr1 Signaling Pathway In Oncology Drug Pipeline Update lists ...  |  read more...
USD 6,750
Hedgehog Signaling Pathway in Oncology Drug Pipeline Update 2015
6/17/2015 | published by: BioSeeker Group AB
... today 154 companies plus partners developing 193 Hedgehog pathway targeting drugs in 875 developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years ...  |  read more...
USD 6,750
Hematological Cancers Drug Pipeline Update 2015
6/17/2015 | published by: BioSeeker Group AB
... 950 hematological cancer drugs in 2254 developmental projects in cancer. In addition, there are 10 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 295 drugs. Hematological Cancers ...  |  read more...
USD 8,850
IL-9 Signaling Pathway in Oncology Drug Pipeline Update 2015
6/17/2015 | published by: BioSeeker Group AB
... developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 33 drugs. Il-9 Signaling Pathway In Oncology Drug Pipeline Update ...  |  read more...
USD 4,485
Immunotherapy in Oncology Drug Pipeline Update 2015
6/17/2015 | published by: BioSeeker Group AB
... of antibodies, vaccines, and immunostimulators in oncology drug development into one source. There are today 760 companies plus partners developing 1331 cancer immunotherapy drugs in 3660 developmental projects in cancer. In addition, there are 19 ...  |  read more...
USD 11,025
Leptin Signaling Pathway in Oncology Drug Pipeline Update 2015
6/17/2015 | published by: BioSeeker Group AB
... partners developing 470 Leptin pathway targeting drugs in 1757 developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 219 ...  |  read more...
USD 6,750
Leukemia Drug Pipeline Update 2015
6/17/2015 | published by: BioSeeker Group AB
... projects in cancer. In addition, there are 6 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 157 drugs. Leukemia Drug Pipeline Update lists all drugs and gives ...  |  read more...
USD 6,750
Liver Cancer Drug Pipeline Update 2015
6/17/2015 | published by: BioSeeker Group AB
... drugs over the last years amount to another 65 drugs. Liver Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 205 ...  |  read more...
USD 4,485
Notch Signaling Pathway in Oncology Drug Pipeline Update 2015
6/17/2015 | published by: BioSeeker Group AB
... are today 309 companies plus partners developing 369 Notch pathway targeting drugs in 1485 developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last ...  |  read more...
USD 6,750
Ovarian Cancer Drug Pipeline Update 2015
6/17/2015 | published by: BioSeeker Group AB
... an important secondary indication for existing and pipeline drugs. There are today 314 companies plus partners developing 418 drugs targeting ovarian cancer in development. In addition, there are 6 suspended drugs and the accumulated number ...  |  read more...
USD 6,750
Prostate Cancer Drug Pipeline Update 2015
6/17/2015 | published by: BioSeeker Group AB
... been eroded by the launch of various LHRH agonist depot formulations. Safety concerns with AstraZeneca`s Casodex (bicalutamide) have also seen a significant proportion of physicians switching to alternatives. Establishing the optimal timing of antihormonal therapy ...  |  read more...
USD 6,750
< prev 1    3  4  5  6  7  8  9  10